Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint

A randomized phase 3 trial designed to assess the addition of tiragolumab to atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer failed to meet its co-primary endpoint of PFS.
Tiragolumab (Genentech) is a novel immune checkpoint inhibitor with an intact Fc region. The agent selectively binds to TIGIT, a novel inhibitory immune checkpoint that suppresses the immune response to cancer, according to a Genentech-issued press release.
Atezolizumab (Tecentriq, Genentech) is an anti-PD-L1 monoclonal antibody.
The global SKYSCRAPER-02 trial included 490

A randomized phase 3 trial designed to assess the addition of tiragolumab to atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer failed to meet its co-primary endpoint of PFS.
Tiragolumab (Genentech) is a novel immune checkpoint inhibitor with an intact Fc region. The agent selectively binds to TIGIT, a novel inhibitory immune checkpoint that suppresses the immune response to cancer, according to a Genentech-issued press release.
Atezolizumab (Tecentriq, Genentech) is an anti-PD-L1 monoclonal antibody.
The global SKYSCRAPER-02 trial included 490